Skip to main content

Hereditary Angioedema clinical trials at University of California Health

2 in progress, 1 open to eligible people

Showing trials for
  • STAR-0215 in Participants With Hereditary Angioedema

    open to eligible people ages 18 years and up

    The goal of this clinical trial is to test the drug STAR-0215 in participants with hereditary angioedema (HAE). One group of participants will get 1 dose of STAR-0215, and two other groups will get 2 doses of STAR-0215. Researchers will study the effects of STAR-0215 in participants with HAE as this is the first time that the drug has been given to participants with HAE.

    at UCSD

  • Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema

    Sorry, in progress, not accepting new patients

    This is a Phase 1/2, single-arm, open-label, dose-escalation and dose-expansion study of BMN 331 for the treatment of hereditary angioedema (HAE) due to C1 Esterase Inhibitor (C1-INH) protein deficiency. The study drug BMN 331is identified as AAV5 hSERPING1, an adeno-associated virus (AAV5)-based gene therapy vector that expresses wild-type human C1 Esterase Inhibitor (hC1-INH), under the control of a liver-selective promoter, and is being developed for the treatment of HAE with C1-INH deficiency. The pharmaceutical form of BMN 331 is a solution for intravenous infusion.

    at UCSD

Last updated: